Trump Fast-Tracks Psychedelic Drug Reviews: New Era for Medical Use?

President Trump has directed an accelerated review of psychedelics like ibogaine, endorsed by veterans and some lawmakers for severe depression and PTSD treatment despite safety risks. The FDA will issue priority vouchers, allowing quick approvals if aligned with national priorities, marking a significant policy shift.

The Trump administration is taking rapid action to reevaluate certain psychedelic drugs for medical purposes. In an executive order signed by President Trump, drugs like ibogaine are under consideration for faster approval processes due to their potential in treating severe depression and PTSD, as advocated by veterans and lawmakers.

Despite its current classification as a high-risk illegal substance, ibogaine has shown promise in treating hard-to-manage conditions, though it carries known safety risks, including heart problems. Recent studies have indicated potential benefits for veterans diagnosed with PTSD and traumatic brain injuries.

Joining the bipartisan effort, the FDA plans to expedite the review process by issuing national priority vouchers. This effort aligns with an emerging shift towards bipartisan support for exploring psychedelics' medicinal purposes in the United States.

(With inputs from agencies.)